Updates in Bladder Cancer Treatment
In this series, Dr. Carissa Chu provides the latest updates on emerging therapies for bladder cancer from the American Urological Association’s 2024 Annual Meeting and the clinical implications of these findings.
Episodes 1-7 of 7
Collaborative Insights to Solve the Puzzle of Bladder Cancer
CME/CECollaborative Insights to Solve the Puzzle of Bladder Cancer
Advancements in GU Cancers: Key Data from AUA 2024
CME/CEAdvancements in GU Cancers: Key Data from AUA 2024
Phase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
Oncology and HematologyPhase-3 SunRISe-2: TAR-200 Plus Cetrelimab Versus Chemoradiotherapy in Muscle-Invasive Bladder Cancer
TAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Oncology and HematologyTAR-210 vs Intravesical Chemotherapy in Intermediate-Risk Non–Muscle-Invasive Bladder Cancer With Susceptible FGFR Alterations: MoonRISe-1
Updates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyUpdates From SunRISe-3: TAR-200 Plus Cetrelimab or TAR-200 Versus Intravesical BCG in High-Risk Non–Muscle-Invasive Bladder Cancer
SunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
Oncology and HematologySunRISe-1: TAR-200 in BCG-Unresponsive High-Risk Bladder Cancer
TAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
Oncology and HematologyTAR-200 vs Intravesical Chemotherapy After BGC: Phase 3 Sun-RISe-5 in Non–Muscle-Invasive Bladder Cancer
